Results 41 to 50 of about 7,984 (250)

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen   +12 more
wiley   +1 more source

Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study [PDF]

open access: yes, 2014
BACKGROUND: The purpose of this analysis is to evaluate the safety and effectiveness of insulin initiation with once-daily insulin detemir (IDet) or insulin glargine (IGlar) in real-life clinical practice in Turkish patients with type 2 diabetes mellitus
Anne Louise Svendsen   +4 more
core   +1 more source

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz   +8 more
wiley   +1 more source

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2009
Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30 ...
Gregory E Peterson
doaj  

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia

open access: yesClinicoEconomics and Outcomes Research, 2020
Asrul Akmal Shafie,1 Chin Hui Ng2 1Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Penang, Malaysia; 2Pharmacy Department, Hospital Raja Permaisuri Bainun, Ipoh 30450, Perak, MalaysiaCorrespondence: Asrul Akmal ...
Shafie AA, Ng CH
doaj  

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

open access: yesThe FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source

Minimizing hypoglycemia while maintaining glycemic control in diabetes [PDF]

open access: yes, 2008
In the accompanying Perspective, Cryer identifies a number of different areas where therapeutic interventions have the potential to reduce hypoglycemia without compromising glycemic control.
Heller, S.
core   +3 more sources

Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 5, 2 February 2026.
Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner   +8 more
wiley   +1 more source

Insulin detemir in the treatment of type 1 and type 2 diabetes

open access: yesVascular Health and Risk Management, 2006
Jean-Christophe Philips, André ScheenDivision of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU Sart-Tilman, University of Liège, Liège, Belgium Abstract: Insulin detemir is a soluble long-acting human ...
Jean-Christophe Philips   +1 more
doaj  

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients

open access: yesInternational Journal of Endocrinology, 2013
Aims. To examine the potential differences between multiple daily injection (MDI) regimens based on new long-acting insulin analogues (glargine or detemir) plus prandial insulin aspart and continuous subcutaneous insulin aspart infusion (CSII) in ...
Wen-shan Lv   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy